Ozmosi | Selodenoson Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Selodenoson

Alternative Names: selodenoson, dti-0009, dti0009, dti 0009
Clinical Status: Inactive
Latest Update: 2005-06-24
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: ADORA1 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Aderis
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Atrial Fibrillation

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT00040001

DTI-0009/003

P2

Completed

Atrial Fibrillation

None

2019-03-21

Treatments

Recent News Events

Date

Type

Title